PharmaCyte Biotech’s recently appointed CEO Kenneth L. Waggoner, is solely focused on hitting major milestones and marks 2015 as a banner year for PharmaCyte Biotech, Inc. (OTCQB:PMCB), a Silver Spring, MD-based clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®.
Read more →SILVER SPRING, Md., May 6, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today announced that the Institute of Virology at the University of Veterinary Medicine Vienna, one of the partners in PharmaCyte Biotech’s
Read more →SILVER SPRING, Md., April 20, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today announced that the world class team of scientists, physicians and academics that make up its international Diabetes Consortium
Read more →SILVER SPRING, Md., April 14, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), announced today that Thomas Liquard has joined its Board of Directors and will become Chairman of the Audit Committee. Mr. Liquard
Read more →SILVER SPRING, MD, April 10, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that Prof. Ann Simpson (a member of PharmaCyte
Read more →Newswise — Ascites is the buildup of fluid in the abdominal cavity that occurs in patients with certain diseases. Ascites caused by cancer is called malignant ascites and accounts for 10% of people with ascites. Malignant ascites appears most often in people with breast, colon, liver, gastrointestinal tract (stomach and intestines), and ovarian, pancreatic, and
Read more →SILVER SPRING, MD, March 27, 2015 (GLOBE NEWSWIRE) – PharmaCyte Biotech, Inc. (OTCQB: PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the genetically modified cells that are required for its three planned clinical trials have been fully tested
Read more →NEW YORK, NY–(Marketwired – March 18, 2015) – PharmaCyte Biotech (PMCB) is aiming directly at the problem patients with advanced pancreatic cancer face, an inoperable tumor! PharmaCyte owns the exclusive worldwide rights to develop treatments for all types of solid cancerous tumors using its signature Cell-in-a-Box technology combined with low doses of the
Read more →SILVER SPRING, Md., March 16, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box(R), today provided shareholders with an update on developments on progress in its cancer and diabetes programs and at the
Read more →